Skip navigation

DSpace

機構典藏 DSpace 系統致力於保存各式數位資料(如:文字、圖片、PDF)並使其易於取用。

點此認識 DSpace
DSpace logo
English
中文
  • 瀏覽論文
    • 校院系所
    • 出版年
    • 作者
    • 標題
    • 關鍵字
    • 指導教授
  • 搜尋 TDR
  • 授權 Q&A
    • 我的頁面
    • 接受 E-mail 通知
    • 編輯個人資料
  1. NTU Theses and Dissertations Repository
  2. 醫學院
  3. 護理學系所
請用此 Handle URI 來引用此文件: http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/52775
完整後設資料紀錄
DC 欄位值語言
dc.contributor.advisor李芸湘(Yun-Hsiang Lee)
dc.contributor.authorYu-Chen Suen
dc.contributor.author蘇育蓁zh_TW
dc.date.accessioned2021-06-15T16:27:05Z-
dc.date.available2024-01-31
dc.date.copyright2021-02-23
dc.date.issued2021
dc.date.submitted2021-02-05
dc.identifier.citation中文文獻
王貴霞、劉哲銘、呂志得(2005)‧乳癌病患的困擾及擔憂問題‧北醫醫學雜
誌,2(9),844-850。
吳至容、王雅容(2016)‧化學治療導致周邊神經病變之探討‧腫瘤護理雜誌,16(1),25-33。https://doi.org/10.3966/168395442016061601004
吳詩萍、許雅娟(2016)‧初次接受化學治療之癌症老年病人之因應行為與症狀困擾相關性之探討‧護理雜誌,63(6),30-40。
https://doi.org/10.6224/jn.63.6.30
陳美芳、馬鳳歧(2004)‧乳癌手術後婦女症狀困擾與因應策略之相關性探討‧護理雜誌,51(4),37-44。
張承培、黃文盛(2020)‧Lugano classification簡介‧臨床醫學月刊,86(4),
637-644。https://doi.org/10.6666/ClinMed.202010_86(4).0114
衛生福利部國民健康署(2018)‧中華民國105年癌症登記報告‧衛生福利部國民健康署。https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid =269 pid =10227
衛生福利部國民健康署(2018)‧癌症登記線上互動查詢系統‧衛生福利部國民健康署。https://cris.hpa.gov.tw/pagepub/Home.aspx?itemNo =cr.a.10
英文文獻
Abdelmageed Imam, E., Ibrahim, A., Palaian, S., Mohamed Ibrahim, M. (2016). Prevalence of vincristine induced-peripheral neuropathy among Sudanese cancer patients. Journal of Young Pharmacists, 8 (3), 239–243.
https://doi.org/10.5530/jyp.2016.3.12
Adhikari, S., Dongol, R. M., Hewett, Y., Shah, B. K. (2014). Vincristine-induced
blindness: a case report and review of literature. Anticancer Research, 34 (11),
6731-6733.
Anagnostopoulos, F., Kolokotroni, P., Spanea, E., Chryssochoou, M. (2006). The
mini-mental adjustment to cancer (mini-mac) scale: Construct validation with a greek sample of breast cancer patients. Psycho-Oncology, 15 (1), 79–89.
https://doi.org/10.1002/pon.924
American Cancer Society. (2019). Non-Hodgkin lymphoma. Retrieved from
https://www.cancer.org/cancer/non-hodgkin-lymphoma/detection-diagnosis-staging/signs-symptoms.html
Argyriou, A. A., Bruna, J., Marmiroli, P., Cavaletti, G. (2012). Chemotherapy-induced peripheral neurotoxicity (CIPN) : An update.
Critical Reviews in Oncology/Hematology, 82 (1), 51-77. https://doi.org/10.1016/j.critrevonc.2011.04.012
Barton, D. L., Wos, E. J., Qin, R., Mattar, B. I., Green, N. B., Lanier, K. S., Bearden, J. D., Kugler, J. W., Hoff, K. L., Reddy, P. S., Rowland, K. M., Riepl, M., Christensen, B., Loprinzi, C. L., (2011). A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Supportive Care in Cancer, 19, 833–841. https://doi.org/10.1007/s00520-010-0911-0
Barrington, S. F., Mikhaeel, N. G., Kostakoglu, L., Meignan, M., Hutchings, M., Müeller, S. P., Schwartz, L. H., Zucca, E., Fisher, R. I., Trotman, J., Hoekstra, O. S., Hicks, R. J., O'Doherty, M. J., Hustinx, R., Biggi, A., Cheson, B. D. (2014). Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 (27), 3048–3058. https://doi.org/10.1200/JCO.2013.53.5229
Beaven, D., Scerri, J. (2017). Coping with non-Hodgkin’s lymphoma: a qualitative
study of patient perceptions and supportive care needs whilst undergoing
chemotherapy. Supportive Care in Cancer, 25, 2435.
https://doi.org/10.1007/s00520-017-3649-0
Bhat, K. G., Singhal, V., Borker, A. S. (2012). Successful treatment of vincristine induced ptosis and polyneuropathy with pyridoxine and pyridostigmine in a child with acute lymphoblastic leukemia. Indian Journal of Medical and Paediatric Oncology, 33 (3), 185-187.
https://doi.org/10.4103/0971-5851.103152
Carbone, P. P., Kaplan, H. S., Musshoff, K., Smithers, D. W., Tubiana, M. (1971). Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Research, 31 (11), 1860-1861.
Cavaletti, G., Jann, S., Pace, A., Plasmati, R., Siciliano, G., Briani, C., Cocito, D., Padua, L., Ghiglione, E., Manicone, M., Giussani, G., (2006). Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity. Journal of the Peripheral Nervous System, 11 (2), 135-141. https://doi.org/10.1111/j.1085-9489.2006.00078.x
Cavaletti, G., Frigeni, B., Lanzani, F., Mattavelli, L., Susani, E., Alberti, P., Cortinovis, D., Bidoli, P. (2010). Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools. European Journal of Cancer, 46, 479–494.
Chan, C. W., Cheng, H., Au, S. K., Leung, K. T., Li, Y. C., Wong, K. H., Molassiotis A. (2018). Living with chemotherapy-induced peripheral neuropathy: Uncovering the symptom experience and self-management of neuropathic symptoms among cancer survivors. European Journal of Oncology Nursing, 36, 135-141. https://doi.org/10.1016/j.ejon.2018.09.003.
Cleeland, C. S., Farrar, J. T., Hausheer, F. H. (2010). Assessment of cancer-related neuropathy and neuropathic pain. Oncologist, 15 (2) , 13-18. https://doi.org/10.1634/theoncologist.2009-S501
Cohen, S., Kamarck, T., Mermelstein, R. (1983). A global measure of perceived stress. Journal of Health and Social Behavior, 24, 385-396.
Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., van den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P., Gisselbrecht, C. (2002). CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine, 346 (4), 235-242. https://doi.org/10.1056/NEJMoa011795
Costa, T. C., Lopes, M., Anjos, A. C. Y. D., Zago, M. M. F. (2015). Chemotherapy-induced peripheral neuropathies: an integrative review of the literature. Revista da Escola de Enfermagem da USP, 49, 0335-0345.
Dorchin, M., Masoumi Dehshiri, R., Soleiman, S., Manashi, M. (2013). Evaluation of neuropathy during intensive vincristine chemotherapy for non-Hodgkin's lymphoma and Acute Lymphoblastic Leukemia. Iranian journal of pediatric hematology and oncology, 3 (4), 138–142.
Emadi, A., Jones, R. J., Brodsky, R. A. (2009). Cyclophosphamide and cancer: golden anniversary. Nature Reviews Clinical Oncology, 6, 638. https://doi.org/10.1038/nrclinonc.2009.146
Erikson, E. H. (1982). The Life Cycle Completed. New York: WW Norton Norton.
Ezendam, N. P., Nicolaiji, K. A., Kruitwagen, R. P., Pijnenborg, J. M., Vos, M. C., Boll, D., van Bommel, M., Van de Poll-Franse, L. V. (2014). Survivorship care plans to inform the primary care physician: Results from the ROGY care pragmatic cluster randomized controlled trial. Journal of Cancer Survivorship, 8, 595-602. https://doi.org/10.1007/s11764-014-0368-0.
Folkman, S., Lazarus, R. S. (1980). An analysis of coping in a middle-aged community sample. Journal of Health and Social Behavior, 21 (3), 219–239. https://doi.org/10.2307/2136617
Gilchrist, L. S., Tanner, L. R., Ness, K. K. (2017). Short-term recovery of chemotherapy-induced peripheral neuropathy after treatment for pediatric non-CNS cancer. Pediatric Blood Cancer, 64 (1), 180-187. https://doi.org/10.1002/pbc.26204
Grisold, W., Cavaletti, G., Windebank, A. J. (2012). Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro-Oncology, 14 (4), iv45-54. https://doi.org/10.1093/neuonc/nos203
Guilhaumou, R., Solas, C., Bourgarel-Rey, V., Quaranta, S., Rome, A., Simon, N.,
Lacarelle, B., Andre, N. (2011). Impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 genetic polymorphisms on vincristine-induced
neurotoxicity. Cancer Chemotherapy and Pharmacolog, 68 (6):1633-8.
https://doi.org/ 10.1007/s00280-011-1745-2
Gutierrez-Camino, A., Martin-Guerrero, I., Lopez-Lopez, E., Echebarria-Barona, A.,
Zabalza, I., Ruiz, I., Guerra-Merino, I., Garcia-Orad, A. (2016). Lack of
association of the CEP72r- s924607 TT genotype with vincristine-related
peripheral neuropathy during the early phase of pediatric acute lymphoblastic
leukemia treatment in a Spanish population.
Pharmacogenetics and Genomics.26 (2), 100-102.
https://doi.org/ 10.1097/FPC.0000000000000191.
Hajian, S., Mehrabi, E., Simbar, M., Houshyari, M. (2017). Coping Strategies and Experiences in Women with a Primary Breast Cancer Diagnosis. Asian Pacific Journal of Cancer Prevention, 18 (1), 215-224.
https://doi.org/ 10.22034/APJCP.2017.18.1.215.
Haryani, H., Fetzer, S. J., Wu, C. L., Hsu, Y. Y. (2017). Chemotherapy-Induced Peripheral Neuropathy Assessment Tools: A Systematic Review. Oncology Nursing Forum, 44 (3), 111-123. https://doi.org/10.1188/17.Onf.E111-e123
Hernandez-Ledesma, A. L., Rodriguez-Mendez, A. J., Gallardo-Vidal, L. S.,
Trejo-Cruz, G., Garcia-Solis, P., Davila-Esquivel, F. J. (2018). Coping
strategies and quality of life in Mexican multiple sclerosis patients: Physical,
psychological and social factors relationship. Multiple Sclerosis and Related
Disorders, 25, 122-127. https://doi.org/10.1016/j.msard.2018.06.001
https://doi.org/10.1007/s10549-010-1278-0
Hershman, D. L., Lacchetti, C., Dworkin, R. H., Lavoie Smith, E. M., Bleeker, J., Cavaletti, G., Chauhan, C., Gavin, P., Lavino, A., Lustberg, M. B., Paice, J., Schneider, B., Smith, M. L., Smith, T., Terstriep, S., Wagner-Johnston, N.,
Bak, K., Loprinzi, C. L. (2014). Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. Journal of Clinical Oncology, 32 (18), 1941-1967. https://doi.org/10.1200/jco.2013.54.0914
Hershman, D. L., Till, C., Wright, J. D., Awad, D., Ramsey, S. D., Barlow, W. E.,
Minasian, L. M., Unger, J. (2016). Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 (25), 3014–3022. https://doi.org/10.1200/JCO.2015.66.2346
Horvat, M., Zadnik, V., Južnič Šetina, T., Boltežar, L., Pahole Goličnik, J., Novaković, S., Jezeršek Novaković, B. (2018). Diffuse large B-cell lymphoma: 10 years' real-world clinical experience with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone. Oncology Letters, 15 (3), 3602-3609. https://doi.org/10.3892/ol.2018.7774
Hughes, N., Closs, S. J. and Clark, D. (2009). Experiencing cancer in old age: a qualitative systematic review. Qualitative Health Research, 19 (8). 1139-1153. https://doi.org/10.1177/1049732309341715
Kang, D., Cho, J., Kim, I. R., Kim, M. K., Kim, W. S., Kim, S. J. (2018). Health-Related Quality of Life in Non-Hodgkin Lymphoma Survivors: A Prospective Cohort Study. Cancer Research and Treatment, 50 (4), 1051-1063. https://doi.org/10.4143/crt.2017.207
Kerckhove, N., Collin, A., Condé, S., Chaleteix, C., Pezet, D., Balayssac, D. (2017). Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review. Frontiers in Pharmacology, 8 (86).
https://doi.org/10.3389/fphar.2017.00086
Kleckner, I. R., Kamen, C., Gewandter, J. S., Mohile, N. A., Heckler, C. E., Culakova, E., . . . Mustian, K. M. (2018). Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial. Supportive Care in Cancer, 26 (4), 1019-1028. https://doi.org/10.1007/s00520-017-4013-0
Kvillemo, P., Bränström, R. (2014). Coping with breast cancer: a meta-analysis. PLoS One, 9 (11): e112733.
https://doi.org/10.1371/journal.pone.0112733 PMID: 25423095
Lazarus, R. S., Folkman, S. (1984), Stress, appraisal and coping. New York:
Springer Publishing Company.
Legha, S. S. (1986). Vincristine neurotoxicity. Pathophysiology and management.
Journal of Medical Toxicology, 1 (6), 421-427. https://doi.org/10.1007/bf03259853
Li, K., Giustini, D., Seely, D. (2019). A systematic review of acupuncture for chemotherapy-induced peripheral neuropathy. Current oncology, 26 (2), e147–e154. https://doi.org/10.3747/co.26.4261
Lichtman, S. M., Hurria, A., Cirrincione, C. T., Seidman, A. D., Winer, E., Hudis, C.,
Cohen, H. J., Muss, H. B., Cancer and Leukemia Group B (2012). Paclitaxel
efficacy and toxicity in older women with metastatic breast cancer: combined
analysis of CALGB 9342 and 9840. Annals of oncology : official journal of the
European Society for Medical Oncology, 23 (3), 632–638.
https://doi.org/10.1093/annonc/mdr297
Lynn, M. R. (1986). Determination and quantification of content validity. Nursing
Research, 35 (6), 382-385.
Matsuoka, A., Mitsuma, A., Maeda, O., Kajiyama, H., Kiyoi, H., Kodera, Y., . . . Ando, Y. (2016). Quantitative assessment of chemotherapy-induced peripheral neurotoxicity using a point-of-care nerve conduction device. Cancer Science, 107 (10), 1453-1457. https://doi.org/10.1111/cas.13010
Menshadi, N., Bar-Tal, Y., Barnoy, S. (2013). The Relationship Between Learned Resourcefulness and Cancer-Related Fatigue in Patients With Non-Hodgkin Lymphoma. Oncology Nursing Forum, 40, 133-138. https://doi.org/10.1188/13.ONF.133-138
Miltenburg, N. C., Boogerd, W. (2014). Chemotherapy-induced neuropathy: A
comprehensive survey. Cancer Treatment Reviews, 40 (7), 872-882.
https://doi.org/10.1016/j.ctrv.2014.04.004
Mohammed, R., Milne, A., Kayani, K., Ojha, U. (2019). How the discovery of rituximab impacted the treatment of B-cell non-Hodgkin's lymphomas. Journal of Blood Medicine, 10, 71-84. https://doi.org/10.2147/jbm.S190784
Mols, F., Beijers, T., Vreugdenhil, G., van de Poll-Franse, L. (2014). Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review. Supportive Care in Cancer, 22 (8), 2261-2269. https://doi.org/10.1007/s00520-014-2255-7
Mora, E., Smith, E. M., Donohoe, C., Hertz, D. L. (2016). Vincristine-induced peripheral neuropathy in pediatric cancer patients. American Journal of Cancer Research, 6 (11), 2416-2430.
Moreno, A., Colon-Otero, G., Solberg, L. A., Jr. (2000). The prednisone dosage in the CHOP chemotherapy regimen for non-Hodgkin's lymphomas(NHL): is there a standard? Oncologist, 5 (3), 238-249.
National Cancer Institute Cancer. (2017), Common Terminology Criteria for Adverse Events Version 5.0, https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf
National Cancer Institute. (2018), Surveillance, Epidemiology, and End Results (SEER) Program: Non-Hodgkin Lymphoma, https://seer.cancer.gov/statfacts/html/nhl.html
Nikanjam, M., Sun, A., Albers, M., Mangalindin, K., Song, E., Vempaty, H., Sam, D., Capparelli, E. V. (2018). Vincristine-associated Neuropathy With Antifungal Usage: A Kaiser Northern California Experience. Journal of Pediatric Hematology/Oncology, 40 (5), e273-e277. https://doi.org/10.1097/mph.0000000000001220
Nipp, R. D., El-Jawahri, A., Fishbein, J. N., Eusebio, J., Stagl, J. M., Gallagher, E. R., Park, E. R., Jackson, V. A., Pril, W., Greer, J. A., Temel, J. S. (2016). The relationship between coping strategies, quality of life, and mood in patients with incurable cancer. Cancer, 122(13), 2110–2116. https://doi.org/10.1002/cncr.30025
Okada, N., Hanafusa, T., Sakurada, T., Teraoka, K., Kujime, T., Abe, M., Shinohara, Y., Kawazoe, K., Minakuchi, K. (2014). Risk Factors for Early-Onset Peripheral Neuropathy Caused by Vincristine in Patients with a First Administration of R-CHOP or R-CHOP-Like Chemotherapy. Journal of Clinical Medicine, 6 (4), 252-260. https://doi.org/10.14740/jocmr1856w
Oerlemans, S., Issa, D. E., van den Broek, E. C., Nijziel, M. R., Coebergh, J. W., Huijgens, P. C., Huijgens, P. C., Mols, F., van de Poll-Franse, L. V. (2014). Health-related quality of life and persistent symptoms in relation to (R-) CHOP14, (R-) CHOP21, and other therapies among patients with diffuse large B-cell lymphoma: results of the population-based PHAROS-registry. Annals of Hematology, 93 (10), 1705-1715. https://doi.org/10.1007/s00277-014-2099-8
Pachman, D. R., Qin, R., Seisler, D. K., Smith, E. M., Beutler, A. S., Ta, L. E., … Loprinzi, C. L. (2015). Clinical Course of Oxaliplatin-Induced Neuropathy: Results from the Randomized Phase III Trial N08CB (Alliance). Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 33 (30), 3416–3422. https://doi.org/10.1200/JCO.2014.58.8533
Pike, C. T., Birnbaum, H. G., Muehlenbein, C. E., Pohl, G. M., Natale, R. B. (2012). Healthcare Costs and Workloss Burden of Patients with Chemotherapy-Associated Peripheral Neuropathy in Breast, Ovarian, Head and Neck, and Nonsmall Cell Lung Cancer. Chemotherapy Research and Practice, 2012. https://doi.org/10.1155/2012/913848
Plosker, G. L., Figgitt, D. P. (2003). Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs, 63 (8), 803-843.
Postma, T. J., Benard, B. A., Huijgens, P. C., Ossenkoppele, G. J., Heimans, J. J.
(1993). Long-term effects of vincristine on the peripheral nervous system.
Journal of Neuro-Oncology, 15(1), 23-27. https://10.1007/BF01050259.
Postma, T. J., Heimans, J. J. (2000). Grading of chemotherapy-induced peripheral neuropathy. Annals of Oncology, 11 (5), 509-513. https://doi.org/10.1023/A:1008345613594
Postma, T. J., Aaronson, N. K., Heimans, J. J., Muller, M. J., Hildebrand, J. G., Delattre, J. Y., Hoang-Xuan, K., Lantéri-Minet, M., Huddart, R., Moynihan, C., Maher, J., Lucey, R. (2005). The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. European Journal of Cancer, 41 (8), 1135-1139. https://doi.org/10.1016/j.ejca.2005.02.012
Quasthoff, S., Hartung, H. P.(2002). Chemotherapy-induced peripheral neuropathy. Journal of Neurology, 249 (1), 9-17. https://doi.org/10.1007/pl00007853
Rummel, M. J., Niederle, N., Maschmeyer, G., Banat, G. A., von Grünhagen, U., Losem, C., . . . Brugger, W. (2013). Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet, 381 (9873), 1203-1210.
https://doi.org/10.1016/s0140-6736(12)61763-2
Ryberg, M., Nielsen, D., Skovsgaard, T., Hansen, J., Jensen, B. V., Dombernowsky, P. (1998). Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. Journal of Clinical Oncology, 16 (11), 3502-3508. https://doi.org/10.1200/jco.1998.16.11.3502
Sahenk, Z., Brady, S. T., Mendell, J. R. (1987). Studies on the pathogenesis of vincristine-induced neuropathy. Muscle Nerve, 10 (1), 80-84. https://doi.org/10.1002/mus.880100115
Said, J. W. (2013). Aggressive B-cell lymphomas: how many categories do we need? Modern Pathology, 26 (1), S42-56. https://doi.org/10.1038/modpathol.2012.178
Sawaki, A., Miyazaki, K., Yamaguchi, M., Takeuchi, T., Kobayashi, K., Imai, H.,
Tawara, I., Ono, R., Nosaka, T., Katayama, N. (2020). Genetic polymorphisms
and vincristine-induced peripheral neuropathy in patients treated with rituximab,
cyclophosphamide, doxorubicin, vincristine, and prednisone therapy.
International Journal of Hematology, 111 (5), 686-691.
https://doi.org/10.1007/s12185-020-02832-x
Scheel, A., Beijers, A. J., Mols, F., Faber, C. G., Vreugdenhil, G. (2014). Chemotherapy-induced peripheral neuropathy; impact on quality of life. Nederlands Tijdschrift voor Geneeskunde, 158, A7455.
Schou, I., Ekeberg, O., Sandvik, L., Hjermstad, M. J., Ruland, C. M. (2005). Multiple predictors of health-related quality of life in early stage breast cancer. Data from a year follow-up study compared with the general population. Quality of Life Research, 14 (8), 1813-1823. https://doi.org/10.1007/s11136-005-4344-z
Seretny, M., Currie, G. L., Sena, E. S., Ramnarine, S., Grant, R., MacLeod, M. R., Colvin, L. A., Fallon, M. (2014). Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain, 155(12), 2461-2470. https://doi.org/10.1016/j.pain.2014.09.020
Smith, E. M., Beck, S. L., Cohen, J. (2008). The total neuropathy score: a tool for measuring chemotherapy-induced peripheral neuropathy. Oncology Nursing Forum, 35 (1), 96-102. https://doi.org/10.1188/08.Onf.96-102
Smith, E. M., Pang, H., Cirrincione, C., Fleishman, S., Paskett, E. D., Ahles, T., Bressler, L. R., Fadul, C. E., Knox, C., Le-Lindqwister, N., Gilman, P. B., Shapiro, C. L., Alliance for Clinical Trials in Oncology (2013). Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. Journal of the American Medical Association, 309 (13), 1359–1367. https://doi.org/10.1001/jama.2013.2813
Smith, S. K., Crespi, C. M., Petersen, L., Zimmerman, S., Ganz, P. A. (2010). The impact of cancer and quality of life for post-treatment non-Hodgkin lymphoma survivors. Psycho-oncology, 19 (12), 1259–1267. https://doi.org/10.1002/pon.1684
Speck, R. M., DeMichele, A., Farrar, J. T., Hennessy, S., Mao, J. J., Stineman, M. G., Barg, F. K. (2012). Scope of symptoms and self-management strategies for chemotherapy-induced peripheral neuropathy in breast cancer patients. Support Care Cancer, 20 (10), 2433-2439. https://doi.org/10.1007/s00520-011-1365-8
Stubblefield, M. D., Burstein, H. J., Burton, A. W., Custodio, C. M., Deng, G. E.,
Ho, M., Junck, L., Morris, G., Paice, J. A., Tummala, S., Von Roenn, J. H.
(2009). NCCN Task Force Report: Management of Neuropathy in Cancer,
Journal of the National Comprehensive Cancer Network, 7(Suppl_5), S-1-S-26.
Tariq, A., Aziz, M. T., Mehmood, Y., Asghar, S. A., Khurshid, A. (2018). Clinical Response to CHOP vs. R-CHOP in Adult Patients with Diffuse Large B-Cell Lymphomas. Asian Pacific Journal of Cancer Prevention, 19 (5), 1181-1184. https://doi.org/10.22034/apjcp.2018.19.5.1181
Teoh, D., Smith, T. J., Song, M., Spirtos, N. M. (2018). Care After Chemotherapy: Peripheral Neuropathy, Cannabis for Symptom Control, and Mindfulness. American Society of Clinical Oncology Educational Book, 38, 469-479. https://doi.org/10.1200/edbk_209437
Tofthagen, C. (2010). Patient perceptions associated with chemotherapy-induced peripheral neuropathy. Clinical Journal of Oncology Nursing, 14 (3), E22-28. https://doi.org/10.1188/10.Cjon.E22-e28
Tofthagen, C., Gonzalez, L., Visovsky, C., Akers, A. (2013). Self-management of oxaliplatin-related peripheral neuropathy in colorectal cancer survivors. Chemotherapy research and practice, 2013, 547932. https://doi.org/10.1155/2013/547932
Trobaugh-Lotrario, A. D., Smith, A. A., Odom, L. F. (2003). Vincristine neurotoxicity in the presence of hereditary neuropathy. Medical and Pediatric Oncology, 40 (1), 39-43. https://doi.org/10.1002/mpo.10105
Tuncay, T. (2014). Coping and quality of life in Turkish women living with ovarian
cancer. Asian Pacific Journal of Cancer Prevention, 15 (9), 4005-4012.
https://doi.org/10.7314/apjcp.2014.15.9.4005
van de Velde, M. E., Kaspers, G. L., Abbink, F. C. H., Wilhelm, A. J., Ket, J. C. F., van den Berg, M. H. (2017). Vincristine-induced peripheral neuropathy in children with cancer: A systematic review. Critical Reviews in Oncology/Hematology, 114, 114-130. https://doi.org/10.1016/j.critrevonc.2017.04.004
Visovsky, C., Collins, M., Abbott, L., Aschenbrenner, J., Hart, C. (2007). Putting evidence into practice: Evidence-based interventions for chemotherapy - induced peripheral neuropathy. Clinical Journal of Oncology Nursing, 11, 901-913.
Wang, A. W. T., Cheng, C. P., Chang, C. S., Chen, D. R., Chen, S. T., Shieh, V., Lo, A., Hsu, W. Y. (2018). Does the factor structure of the Brief COPE fit different types of traumatic events? A test of measurement invariance. European Journal of Psychological Assessment, 34 (3), 162-173.
Watkins, S. M., Griffin, J. P. (1978). High incidence of vincristine-induced neuropathy in lymphomas. The British Medical Journal, 1 (6113), 610-612. https://doi.org/10.1136/bmj.1.6113.610
Windebank, A. J., Grisold, W. (2008). Chemotherapy-induced neuropathy. Journal of the Peripheral Nervous System, 13 (1), 27-46.
https://doi.org/10.1111/j.1529-8027.2008.00156.x
Wong, M. L., Cooper, B. A., Paul, S. M., Abrams, G., Topp, K., Kober, K. M., . . . Miaskowski, C. (2019). Age-related differences in patient-reported and objective measures of chemotherapy-induced peripheral neuropathy among cancer survivors. Supportive Care in Cancer, 27 (10), 3905-3912
https://doi.org/10.1007/s00520-019-04695-3
Yang, Y. H., Lin, J. K., Chen, W. S., Lin, T. C., Yang, S. H., Jiang, J. K., Chang, S. C., Lan, Y. Z., Lin, C. C., Yen, C. C., Tzeng, C. H., Wang, W. S., Chiang, H. L., Teng, C. J., Teng, H. W. (2012). Duloxetine improves oxaliplatin-induced neuropathy in patient with colorectal cancer: an open-label pilot study. Support Care Cancer, 20, 1491-1497.
https://doi.org/10.1007/s00520-011-1237-2
dc.identifier.urihttp://tdr.lib.ntu.edu.tw/jspui/handle/123456789/52775-
dc.description.abstract化學治療(R)-CHOP為非何杰金氏淋巴癌主要治療處方,但其中化學藥物Vincristine相關周邊神經病變是造成病人生活極大困擾的長期副作用。然而,化療相關周邊神經病變仍缺乏具體有效的預防與治療策略,臨床上,多數患者會自行發展出個人因應策略克服症狀造成的生活困擾,但在因應策略選擇與其有效性為何目前仍尚無相關研究,因此,本研究將針對此部分進行深入探討。
本研究為橫斷式之描述性相關性研究,於中部某醫學中心血液腫瘤科門診、門診化療室及病房,以立意取樣針對123位非何杰金氏淋巴癌的患者進行收案。研究工具包含:歐洲癌症治療與研究組織生活品質核心問卷-周邊神經病變、特定於VIPN相關因應策略有效性量表,並使用整體神經病變(臨床版)進行化療相關周邊神經病變的評估,最後以描述性及推論性統計進行分析。
研究結果顯示 (1)以歐洲癌症治療與研究組織生活品質核心問卷-周邊神經病變進行症狀嚴重度評估,共102位患者自覺有症狀,其中以手麻木、腳抽筋和腳麻木最嚴重,而施測者以整體神經病變(臨床版)向每位患者進行測試,共61位患者出現神經受損症狀,尤其以肌腱反射最為明顯 (2)化療相關周邊神經病變的自我評估與理學檢查嚴重度,皆與年齡呈現顯著正相關 (3)具Vincristine相關周邊神經病變的患者於症狀因應的整體有效性平均為5.17分,心理因應的整體有效性平均為6.15分,而心理因應有效性和自我評估症狀嚴重度呈現顯著負相關,尤其與感覺神經症狀呈現顯著低度負相關,症狀因應有效性則未見顯著差異。
結論:臨床評估建議仍以病人自我評估的化療相關周邊神經病變症狀為主,讓病人定期自我檢視症狀的變化,以回歸病人為中心的照護,必要時,再配合整體神經病變(臨床版)評估,以提供最適當的時機轉介病人進一步復健科神經學相關檢測,並可提供本研究之VIPN的因應策略做為臨床照護之建議。
zh_TW
dc.description.abstractBackground: Vincristine-induced peripheral neuropathy(VIPN) is the most common long-term side effect of chemotherapy in patients with non-Hodgkin's Lymphoma (NHL).However, there is still no specific effective intervention to prevent or treat it. In clinical settings, most of patients will develop their own coping strategies to overcome the distress of VIPN for reducing the impact of life. At the same time, there is still few studies focused on coping strategies and its effectiveness which specific to the VIPN symptom in these patients. Thus, this study will address these issues.
Methods: This is a description and correlation study, using a cross-sectional study
design. Total 123 patients with NHL will be recruited from outpatient department,
outpatient chemotherapy room and ward in a medical center in central Taiwan. Data will
be collected by the European Organization for Research and Treatment of Cancer Core
Quality of Life Questionnaire -CIPN20 (EORTC-QLQ-CIPN20),Specific to the
VIPN-related Coping Strategy Effectiveness Scale(VIPN-COPE). The Total Neuropathy
Score- clinical (TNSc) will be used for objective assessment of VIPN. For statistical
analysis, the differences between the severity of VIPN and clinical related variables will
be analyzed by Mann-Whitney U test and Kruskal–Wallis test, and the correlation
between variables will be analyzed by Spearman's rank-order correlation.
Results: The finding included that (1)102 patients had self-reported VIPN symptoms by EORTC-QLQ-CIPN20 questionare, and 61 patients were reported VIPN by TNSc test. The common symptoms included fingers/toes numbness, reduced deep tendon reflex, and leg cramps. (2) The severity of self-reported and physical examination of VIPN is significantly positively correlated with age.(3) It was more effective to use psychological coping than symptom coping in patients with VIPN. And effectiveness of psychological coping was significantly negatively correlation with self-reported severity of VIPN, especially with sensory neurological symptoms.
Conclusion: The self-reported VIPN severity would be better to help clinicians understand the patient’s distressing symptoms, and physical examination could early diagnose whether the patients had potential VIPN symptoms. As there were no effective treatments or prevention strategies for VIPN, how to cope with symptoms had become very important. The coping strategied in this study could be used as a reference for clinical care.
en
dc.description.provenanceMade available in DSpace on 2021-06-15T16:27:05Z (GMT). No. of bitstreams: 1
U0001-0502202113084800.pdf: 2770073 bytes, checksum: 65a5ad4b50e9f6f4235162884fd3ef81 (MD5)
Previous issue date: 2021
en
dc.description.tableofcontents目錄
誌謝………………………………………………………………………………………i
中文摘要………………………………………………………………………………...ii
英文摘要……………………………………………………………………………......iii
第一章 緒論.....................................................................................................................1
第一節 研究動機與重要性.....................................................................................1
第二節 研究目的.....................................................................................................4
第二章 文獻查證.............................................................................................................5
第一節 非何杰金氏淋巴癌及治療概況.................................................................5
第二節 化學藥物治療相關周邊神經病變.............................................................9
第三節 化療相關周邊神經病變之相關因應策略.............................................. 16
第三章 研究方法.......................................................................................................... 20
第一節 研究設計.................................................................................................. 20
第二節 研究對象及場所...........................……………........................................21
第三節 研究假設...................................................................................................22
第四節 名詞解釋及操作型定義...........................................................................23
第五節 研究工具...................................................................................................24
第六節 研究流程..….............................................................................................27
第七節 資料處理與分析方法...............................................................................28
第八節 研究倫理考量...........................................................................................29
第四章 研究結果….......................................................................................................30
第一節 非何杰金氏淋巴癌個案之人口學特性與疾病資料分析.......................31
第二節 非何杰金氏淋巴癌個案化療相關周邊神經病變之現況分析...............35
第三節 非何杰金氏淋巴癌個案因應策略使用分析...........................................42
第四節 化療相關周邊神經病變及其相關因素分析...........................................50
第五章 討論……….......................................................................................................54
第一節 非何杰金氏淋巴癌患者接受Vincristine之人口學與疾病治療現況....55
第二節 非何杰金氏淋巴癌患者接受化療後發生周邊神經病變之現況探討...57
第三節 非何杰金氏淋巴癌患者於化療相關周邊神經症狀使用之因應策略...59
第六章 結論與建議.......................................................................................................61
第一節 結論...........................................................................................................61
第二節 研究限制...................................................................................................63
第三節 建議...........................................................................................................64
第七章 參考文獻...........................................................................................................67
中文文獻.................................................................................................................67
英文文獻.................................................................................................................67
附錄一 研究倫理委員會審查通過公文.....................................................................82
附錄二 EORTC-QLQ-CIPN20問卷使用授權同意書...............................................85
圖目錄
圖一 研究架構……………………………………………………………….…20
圖二 研究流程………………………………………………………………….27




表目錄
表1 Ann Arbor Staging System.............................................................................6
表2 非何杰金氏淋巴癌患者之人口學資料......................................................32
表3 非何杰金氏淋巴癌患者之疾病特性資料. ................................................34
表4 化療相關周邊神經病變之理學檢查結果………………………..............35
表5 病患自我評估之化療相關周邊神經病變症狀嚴重度..............................38
表6 自我評估化療相關周邊神經病變症狀嚴重度之發生率………………..39
表7 基本屬性與化療相關周邊神經病變嚴重度之差異性…………………..41
表8 特定於Vincristine相關周邊神經病變因應策略之現況分析..................47
表9 特定於Vincristine相關周邊神經病變整體因應策略有效程度..............49
表10 特定於Vincristine相關周邊神經病變症狀對日常活動的困擾..............49
表11 特定於Vincristine相關周邊神經病變症狀資訊來源及需求符合度.......49
表12 化療相關周邊神經病變嚴重度與年齡相關性…………………….…….50
表13 化療相關周邊神經病變嚴重度與症狀、心理因應有效性之相關性…..52
表14 理學檢查分項嚴重度與自我評估症狀嚴重度、因應有效性之相關性..52
表15感覺與運動神經症狀於自我評估與理學檢查嚴重度之相關性...............52
表16自我評估化療相關周邊神經症狀嚴重度與因應有效性之相關性……...58
dc.language.isozh-TW
dc.subject因應策略zh_TW
dc.subject非何杰金氏淋巴癌zh_TW
dc.subject化療相關周邊神經病變zh_TW
dc.subjectVincristine induced peripheral neuropathyen
dc.subjectcoping strategiesen
dc.subjectnon Hodgkin's Lymphomaen
dc.title探討非何杰金氏淋巴癌存活者之化療相關周邊神經病變的症狀困擾與因應策略zh_TW
dc.titleSymptoms and Coping Strategies for Chemotherapy Induced Peripheral Neuropathy in non-Hodgkin's Lymphoma Survivorsen
dc.typeThesis
dc.date.schoolyear109-1
dc.description.degree碩士
dc.contributor.oralexamcommittee賴裕和(Yeur-Hur Lai),謝松蒼(Sung-Tsang Hsieh)
dc.subject.keyword非何杰金氏淋巴癌,化療相關周邊神經病變,因應策略,zh_TW
dc.subject.keywordnon Hodgkin's Lymphoma,,Vincristine induced peripheral neuropathy,,coping strategies,en
dc.relation.page86
dc.identifier.doi10.6342/NTU202100576
dc.rights.note有償授權
dc.date.accepted2021-02-08
dc.contributor.author-college醫學院zh_TW
dc.contributor.author-dept護理學研究所zh_TW
顯示於系所單位:護理學系所

文件中的檔案:
檔案 大小格式 
U0001-0502202113084800.pdf
  未授權公開取用
2.71 MBAdobe PDF
顯示文件簡單紀錄


系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。

社群連結
聯絡資訊
10617臺北市大安區羅斯福路四段1號
No.1 Sec.4, Roosevelt Rd., Taipei, Taiwan, R.O.C. 106
Tel: (02)33662353
Email: ntuetds@ntu.edu.tw
意見箱
相關連結
館藏目錄
國內圖書館整合查詢 MetaCat
臺大學術典藏 NTU Scholars
臺大圖書館數位典藏館
本站聲明
© NTU Library All Rights Reserved